We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000586
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : April 14, 2016
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

October 27, 1999
October 28, 1999
April 14, 2016
January 1992
June 1994   (Final data collection date for primary outcome measure)
Occurrence of vaso-occlusive (painful) crisis [ Time Frame: Measured during the first 2 years a patient was enrolled in the study ]
Not Provided
Complete list of historical versions of study NCT00000586 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.


In spite of the fact that advances have been made in the management or prevention of some of the complications of sickle cell disease, the management of the most common complication--the painful crisis--is still unsatisfactory, and appropriate methods for its prevention are unknown. The morbidity associated with a painful crisis is much more than the suffering from pain alone. The interference with a normal lifestyle, the resulting obstacles to obtaining an education and holding a job, the risk of narcotics addiction, the cost of multiple hospitalizations, and the financial impact on the family and the individual must all be considered.

Evidence from the Cooperative Study of Sickle Cell Disease (CSSCD) study showed that there is an association between multiple pain events and early death in young adults. If this association is true, then MSH has the potential to not only reduce morbidity but mortality as well. The CSSCD study has shown that over 50 percent of patients with sickle cell disease have at least one crisis per year, and a considerable number have more. These episodes are believed to occur as a result of hemoglobin S within the red cells leading to rigid, non-deformable cells which can no longer traverse the microvasculature and as a result produce obstruction with consequent pain, ischemia, and tissue necrosis.

Previous approaches to the therapy of this group of disorders have included: attempts to modify the hemoglobin molecule so as to prevent polymerization; the use of vasoreactive drugs; and increasing red cell volume. All of these attempts have been abandoned either because of their inefficacy, toxicity, or impracticality. Chronic exchange transfusion programs have been of limited usefulness because of high rates of isoimmunization, iron overload, and risk of transmission of hepatitis and retroviral disease.

The rationale for the present study draws its substance from the observation that patients with higher levels of fetal hemoglobin (Hb F) (particularly the Saudi Arabian group), and infants who also have high Hb F levels have fewer crises. Several myelosuppressive drugs, such as 5-azacytidine and hydroxyurea, have been shown to increase Hb F production. The work with 5-azacytidine has had to be abandoned because of the known risk of malignancy.

Preliminary studies by the investigators and others have shown convincingly that Hb F levels can be increased by administering hydroxyurea to patients over a several month period without producing dangerous levels of myelosuppression. The patients have also had a rise in their red cell life span and hematocrit. Further, it has been reported that these patients had a dramatic decrease in crisis frequency. This agent is readily available to all physicians, and there is evidence that it is being used without adequate justification and, possibly, without adequate monitoring. The timing of this study is therefore critical to ensure that an adequate answer to the question of efficacy is obtained and the risk of inappropriate use minimized.


Phase I has concluded. Phase II, also concluded, was a randomized, double-blind, placebo-controlled trial. Patients in the Phase II trial were recruited from 21 clinics and randomized to receive hydroxyurea or placebo. The hydroxyurea was gradually increased from an initial dose of 15 mg/kg to the maximal level tolerated by each patient in order to maximize red blood cell hemoglobin F(Hb F) content without undue marrow suppression. Changes in Hb F production were monitored in each of the two groups by a variety of laboratory tests. The primary endpoint was a comparison of crisis rates in the treated and control groups. Painful crises were defined as pain lasting longer than four hours, requiring parenteral narcotics for relief, including chest syndrome but excluding ankle ulcer pain. Secondary endpoints included changes in pain severity and duration, psychosocial status, complications of the disease, and reasons for non-compliance with either regimen. Patients were followed for two to three years depending on when they entered the study. Because of the mutagenic nature of hydroxyurea, the use of contraception was a requirement of admission to the study.

The trial was stopped early, on January 14, 1995, instead of in May 1995. The Data and Safety Monitoring Board determined that daily doses of hydroxyurea reduced the frequency of painful episodes and hospital admissions for those crises by about 50 percent.

Beginning in 1996, a five year follow-up of the adult patients in MSH was initiated. The purpose was to ascertain the long-term effects of hydroxyurea in this patient population. Patients were followed annually to determine health status, quality of life, incidence of malignancies, and birth defects in their offspring. In addition, mortality rates were determined so that a comparison could be made between this cohort and the mortality data from the Cooperative Study of Sickle Cell Disease (CSSCD) adult cohort and the normal African-American population mortality data. The follow-up was conducted in three phases. Phase I or the Planning Phase in which the final protocol was developed, lasted three months. Phase II, patient entry between March 1996 and June 1996 and patient follow-up, extended from the fourth to the 48th month. Phase III, patient exit and data analysis, were carried out during the final nine months of the study.

The DSMB stopped MSH Phase III early because the study showed that hydroxyurea substantially reduced the frequency of vaso-occlusive (painful) crises.

Phase 3
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
  • Anemia, Sickle Cell
  • Hematologic Diseases
  • Hemoglobinopathies
Drug: hydroxyurea
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
June 1994
June 1994   (Final data collection date for primary outcome measure)
Men and women, ages 18 to 50, who had at least three emergency room visits or hospitalizations for sickle cell anemia during the year prior to recruitment. Patients with greater than 20 crises per year were included. A total of 295 patients had Hb ss and four had Hb SB thalassemia.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
National Heart, Lung, and Blood Institute (NHLBI)
Not Provided
Principal Investigator: Samuel Charache Johns Hopkins University
Principal Investigator: Michael Terrin Maryland Medical Research Institute
National Heart, Lung, and Blood Institute (NHLBI)
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP